 |
|
|
| |
Three Phase I Drug Interaction Studies Investigating the Next-Generation Maturation Inhibitor GSK3640254 With Oral Contraceptive Ethinyl Estradiol/Levonorgestrel,
Dolutegravir, and Tenofovir Alafenamide/Emtricitabine
|
| |
| |
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs Virtual Meeting, September 28-30, 2020
Reported by Jules Levin
1GlaxoSmithKline, Upper Providence, PA, USA; 2ViiV Healthcare, Branford, CT, USA; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA
Correspondence to Teodora Pene Dumitrescu: teodora.x.pene-dumitrescu@gsk.com
|
| |
|
|
|
|
|
